8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Pfizer raises 2026 guidance after third-quarter revenue holds at $16.6 billion
Filed with the SEC on · Summarized by InvestorsBot
Pfizer reported third-quarter 2026 revenue of $16.6 billion, reported diluted EPS of $0.56 and adjusted diluted EPS of $0.87, while revenue excluding Comirnaty and Paxlovid grew 7% operationally. The company raised full-year revenue guidance to $62.0 billion-$64.0 billion and adjusted diluted EPS guidance to $2.95-$3.05; Pfizer also appointed Cecile Guegan chief financial officer effective November 1, 2026, and recorded a $650 million charge tied to its Innovent Biologics licensing and collaboration agreement.